Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy
Nicola A. Hanania(Baylor College of Medicine), William W. Busse(University of Wisconsin–Madison), Oral Alpan(O&O Alpan (United States)), Irmarie Reyes‐Rivera(Baylor College of Medicine), Mark D. Eisner(Royal Victoria Infirmary), Jin Zhu(Baylor College of Medicine), Dennis A. Wong(Baylor College of Medicine), Daniel L. Hamilos(Baylor College of Medicine), Karin Rosén(Baylor College of Medicine), John J. Condemi(Baylor College of Medicine)
Cited by 550
Related Papers
Lebrikizumab Treatment in Adults with Asthma
|New England Journal of Medicine|2011|1.5k
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
|Journal of Allergy and Clinical Immunology|2001|1.3k
An Official American Thoracic Society Public Policy Statement: Novel Risk Factors and the Global Burden of Chronic Obstructive Pulmonary Disease
|American Journal of Respiratory and Critical Care Medicine|2010|986
Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program
|Journal of Allergy and Clinical Immunology|2007|933
Pulmonary Dead-Space Fraction as a Risk Factor for Death in the Acute Respiratory Distress Syndrome
|New England Journal of Medicine|2002|898